The company plans to start clinical development next year. Its focus is on bispecific antibodies - a form of cancer immunotherapy - that use gamma-delta "surveillance" T cells.
The company is developing tumor-infiltrating lymphocyte therapies that target patient-specific neoantigens. It plans to use the money to fund Phase I/IIa studies in solid tumors.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
The Houston-based company is developing a cell therapy for viral infections in patients with compromised immune systems, which it plans to move into Phase III studies within the next 12 months. AlloVir also raised $120 million in a Series B funding round.
The firm will follow a model similar to that of BridgeBio, partnering with scientific researchers and launching companies to develop and commercialize their products.
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The California-based drugmaker plans to use the money to advance its investigational drugs with MOAs based on immune system responses.
The company aims to develop therapeutics focused on antibodies found in patients who respond well to cancer immunotherapies and develop treatments for those who do not.
Virta Health's approach is designed to help patients lower their hemoglobin A1c levels and reduce or eliminate prescription medications. The goal is to reverse the effects of Type 2 diabetes, and cure it.